Zonisamide: A new antiepileptic drug

Clinical Neuropharmacology

Volumn 22, Issue 4, 1999, Pages 192-200

  Oommen, Kalarickal J ^b,c   Mathews, Sunil ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Compreh Oklahoma Prog for Epilepsy ^*  (United States)

^c Department of Neurology ^*  (United States)

Author keywords

Antiepileptic drugs; Epilepsy; Seizures; Sulfonamide; Zonisamide

Indexed keywords

4 AMINOBUTYRIC ACID; ALCOHOL; AMINOTRANSFERASE; CALCIUM CHANNEL; CALCIUM ION; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; ETHOSUXIMIDE; FREE RADICAL; MACROGOL; NITRAZEPAM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SULTIAME; TRIMETHADIONE; VALPROIC ACID; WITEPSOL; ZONISAMIDE;

ANOREXIA; AREA UNDER THE CURVE; ATAXIA; CLINICAL TRIAL; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; EPILEPSY; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SEIZURE; SEIZURE THRESHOLD;

ADULT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; EPILEPSY; EUROPE; HUMANS; ISOXAZOLES; JAPAN; UNITED STATES;

EID: 0033457967     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Hauser WA, Hesdorffer DC. Facts About Epilepsy. New York: Demos;1991:1.
2. Begley CE, Annegers JF, Lairson DR, et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994;35:1230-43.
3. Mattson RH, Crammer JA, Collins JF, and the VA Epilepsy Cooperative Study Group. Success with alternate anti-epileptic drug selection [abstract]. Epilepsia 1986;27:645.
4. Uno H, Kurokawa M, Masuda Y, Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives and their anticonvulsant activities. J Med Chem 1979;22:180-3.
5. Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung 1993;43:416-8.
6. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7.
7. Matsuda Y, Noguchi H, Karasawa T. Evidence against a significant implication of carbonic anhydrase inhibitory activity of zonisamide in its anticonvulsant effects. Arzneimittelforschung 1994;44:267-9.
8. Kito M, Maehara M, Watanabe K. Antiepileptic drugs-calcium current interaction in cultured human neuroblastoma cells. Seizure 1994;3:141-9.
9. Kito M, Maehara M, Watanbe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996;5:115-9.
10. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413:185-8.
11. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995;22:193-205.
12. Endo A. Effect of zonisamide on neurotransmitter release from hippocampal slice of El mice: A study of neurotransmitter release using an improved experimental system. Okayama Igaku Zasshi 1995; 107:69-78.
13. Komatsu M, Okamura Y, Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neurosciences 1995;21:23-9.
14. Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res 1998;30:153-8.
15. Ito T, Hori M, Masuda Y, et al. 3-Sulfamoylmethyl-1,2-benizsoxazole, a new type of anticonvulsant drug; electroencephalographic profile. Arzneimittelforschung 1980;30:603-9.
16. Ito T, Hori M, Kadokawa T. Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. Epilepsia 1986;27:367-74.
17. Masuda Y, Karasawa T, Shiraishi Y, et al. 3-Sulphamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug: pharmacological profile. Arzneimittelforschung 1980;30:477-83.
18. Suzuki N, Seki T, Yamawaki H, et al. Treatment of paediatric epilepsy with AD-810 (zonisamide-ZNS). Jpn J Paediatr 1987;40 (suppl):3147-52.
19. Yagi K, Seino M, Mihara T, et al. Open clinical trial of a new anti-epileptic drug, zonisamide, on 49 patients with refractory epileptic seizures. Seishin Igaku 1987;29:111-9.
20. Ono T, Yagi K, Seino M. Clinical efficacy and safety of a new antiepileptic drug, zonisamide - a multi-institutional phase III study. Seishin Iyaku 1988;30:471-82.
21. Wagner JG, Sackellares JC, Donofrio PD, Berent S, Sakmar E. Non-linear pharmacokinetics of CI-912 in adult epileptic patients. Ther Drug Monit 1984;6:277-83.
22. Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH. Zonisamide in epilepsy: a pilot study. Epilepsia 1985;26: 212-20.
23. Ito T, Yamaguchi T, Miyizaki H, et al. Pharmacokinetic studies of AD-180, a new antiepileptic compound. Arzneimittelforschung 1982;32:1581-6.
24. 14C] methyl)-1,2-benzisoxazole (AD-810) in men. Arzneimittelforschung 1983;33:961-8.
25. Nagatomi A, Mishima M, Tsuzuki O, Ohdo S, Higuchi S. Utility of a rectal suppository containing the antiepileptic drug zonisamide. Biol Pharmacol Bull 1997;20:892-6.
26. Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steadystate pharmacokinetics of zonisamide, and antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998;38:166-71.
27. Nagatoma I, Akasaki Y, Uchida M, Takigawa M. Alcohol intake decreases brain zonisamide concentration in inbred El mice. Neuroreport 1997;8:391-394.
28. Schentag JJ, Gengo FM, Wilton JH, et al. Influence of phenobarbital, cimetidine and renal disease on zonisamide kinetics [abstract]. Pharm Res 1987;4(suppl):S79.
29. Seidlik P, Brockbrader H, Chang T, Latts J, Sedman A. Effect of food on the oral absorption of zonisamide in normal healthy volunteers. Pharm Res 1986;3(suppl):S158.
30. Tasaki K, Minami T, Ieiri I, Ohtsubo K, Hirakawa Y, Ueda K, Higuchi S. Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding. Brain Dev 1995;17:182-5.
31. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies - our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16:79-85.
32. Seino M, Ohkuma T, Miyasaka M, et al. Efficacy evaluation of AD-180 (zonisamide)-results of a double -blind comparison with carbamezepine (CBZ). Igaku no Ayumi 1988; 144:275-91.
33. Oguni H, Hayashi K, Fukuyama Y, et al. Phase III study of AD-180 [zonisamide (ZNS)], a new antiepileptic in the treatment of pediatric epilepsy. Shonika Rinsho 1988;41(suppl):439-50.
34. Seino M, Miyazaki H, Ito T. Zonisamide (AD-180, CI-912). In: Pisani F, Perucca E, Avanzini G, Richens A, eds. New Antiepileptic Drugs. Amsterdam: Elsevier Science Publishers, 1991:169-74.
35. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and EEG classification of epileptic seizures. Epilepsia 1981;22:489-501.
36. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for the classification of the epilepsies and the epileptic syndromes. Epilepsia 1985;26:268-78.
37. Suzuki Y, Nagai T, Ono J, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997;38:1035-8.
38. Schmidt D, Loiseau P, Jacob R, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15:67-73.
39. Sackellares, JC, Donofrio PD, Wagner JG, Abou-Khalil B, Berent S, Aasved-Hoyt K. Pilot study of zonisamide (1,2-benisoxazole-3-methansulfonamide) in patients with refractory partial seizures. Epilepsia 1985;26:206-11.
40. Leppick IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993;14: 165-73.
41. Oommen KJ, Ferenz GJ, Labadie EL, Scherrer L. ZNS (CI-912): The Arizona experience. Presented at: World Congress of Neurology, October 22-29, 1989; New Delhi, India.
42. Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1998;38:928-31.
43. Minato H, Kikuta C, Fujitani B, Masuda Y. Protective effect of Zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia 1997;38:975-80.
44. Owen AJ, Ijaz S, Miyahita H, Wishart T, Howlett W, Shauib A. Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res 1997;770:115-22.
45. Kanba S, Yagi G, Kamijima K, et al. The first open study of Zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:707-15.
46. Henry TR, Sackellares JC. The Medical Treatment of Epilepsy. New York: Marcel Dekker; 1992:423-7.
47. Okumura A, Hayakawa F, Kuno K, Wantanabe K. Oligohidrosis caused by zonisamide. No To Hattatsu 1996;28:44-7.
48. Shimizu T, Yamashita Y, Satoi M, et al. Heat stroke-like episode in a child caused by zonisamide. Brain Dev 1997; 19:366-8.
49. Taira T. Zonisamide induced tremor-report of two cases. No To Shinkei 1992;44:61-3.
50. Kimura S. Zonisamide-induced behavior disorder in two children. Epilepsia 1994;35:403-5.
51. Maeoka Y, Hara T, Dejima S, Takeshita K. IgA and IgG2 deficiency associated with zonisamide therapy: a case report. Epilepsia 1997; 38:611-3.
52. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996;37:1242-4.
53. Peters DH, Sorkin EM. Zonisamide - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993;45:760-87.
54. Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex-partial seizures. J Neurol Neurosurg Psychiatry 1982;45: 1119-24.
55. Temkin N, Wilensky AJ. New AEDs: are the compounds or the studies ineffective? Epilepsia 1986;27:644-5.
56. Sander J, Trevisol-Bittencourt PC, Hart YM, Patsalos PN, Shorvon SD. The efficacy and long term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res 1990;7:226-9.
57. Chadwick DT, Andrews J, Bates D, and the UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-7.